Predicting Pathologic Complete Response in Esophageal Cancer Using Blood RNA
Author Information
Author(s): Hirohata Ryosuke MD, Yamamoto Yuki PhD, Mimae Takahiro MD, PhD, Hamai Yoichi MD, PhD, Ibuki Yuta MD, PhD, Takahashi Ryou-u PhD, Okada Morihito MD, PhD
Primary Institution: Hiroshima University
Hypothesis
Small ribonucleic acid (sRNA) obtained from blood samples after neoadjuvant therapy could serve as a novel biomarker for predicting pathologic complete response (pCR).
Conclusion
A predictive model using preoperative clinical factors and sRNA can effectively predict pathologic complete response after neoadjuvant chemoradiotherapy.
Supporting Evidence
- 30 out of 99 patients achieved pathologic complete response after treatment.
- The predictive model had an area under the curve of 0.84.
- Clinical factors such as decrease in maximum standardized uptake value were significant predictors.
Takeaway
Doctors can use a special test on blood samples to help figure out if a patient with esophageal cancer will respond well to treatment before surgery.
Methodology
Next-generation sequencing was used to analyze sRNAs from blood samples collected from patients treated with neoadjuvant chemoradiotherapy.
Potential Biases
Potential bias due to the lack of blood samples before treatment and the inability to verify the source of sRNA.
Limitations
The study was a single-center retrospective study with a relatively small sample size.
Participant Demographics
Patients treated with esophagectomy after neoadjuvant chemoradiotherapy between March 2010 and October 2021.
Statistical Information
P-Value
< 0.001
Confidence Interval
95 % confidence interval 8.1–987.5
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website